一分钟看懂
这是一项关于非小细胞肺癌的I 期 / II 期研究，登记的药物或干预包括Opnurasib；TNO155；trametinib；cetuximab；tislelizumab，当前状态为招募中。登记地点显示中国广州、长沙有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Opnurasib；TNO155；trametinib；cetuximab；tislelizumab · I 期 / II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Novartis Investigative Site · 广州
- Novartis Investigative Site · 长沙
公开的入选条件
- * Participant is currently enrolled in a pre-defined Novartis-sponsored study and is receiving opnurasib as single agent or in combination with other study treatment.
- * Participant has received at least 6 cycles of opnurasib in a parent study.
- * Participant is currently deriving clinical benefit from the study treatment, as determined by the Investigator.
- * Participants currently receiving treatment in one of the KontRASt studies, including those who have not experienced disease progression or who are continuing treatment beyond initial disease progression, may be eligible to enroll in the rollover study if, in
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07468071；登记信息更新于 2026-09-17。